X0306 4 2020-11-05 0 0001228627 Ocuphire Pharma, Inc. OCUP 0001830354 Hoffmann Bernhard 37000 GRAND RIVER AVE SUITE 120 FARMINGTON HILLS MI 48335 0 1 0 0 VP of Corp. Dev. and Secretary Common Stock 2020-11-05 4 A 0 100120 A 100120 D Employee Stock Option (right to buy) 0.9 2020-11-05 4 A 0 42867 A 2028-10-01 Common Stock 42867 42867 D Employee Stock Option (right to buy) 1.21 2020-11-05 4 A 0 30110 A 2029-12-27 Common Stock 30110 30110 D Employee Stock Option (right to buy) 1.65 2020-11-05 4 A 0 4226 A 2020-06-30 Common Stock 4226 4226 D The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. The option is fully vested. 3,486 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2021, subject to continued service. 1,373 shares vested on June 30, 2020, and the remaining shares vest in equal monthly installments from July 2020 through December 2021, subject to continued service. /s/ Emily J. Johns, by Power of Attorney 2020-11-09